Generic Risperdal Hits the Market

clipped from blogs.wsj.com Patients looking to save on antipsychotics have a new option. The patent protecting Johnson & Johnson’s blockbuster Risperdal expired yesterday, and today the FDA said it granted approval to Teva Pharmaceuticals to market the first generic version.